- Trial phase
- Phase 3
- Time to market
- Likely 2029 or later. The Phase 3 NEXERA-303 primary completion is estimated at December 2028, with topline data expected in 2029. If positive, an NDA filing would follow, putting potential approval no earlier than 2030.
- Why 4/10
- The next significant binary catalyst for INCA33890 is the Phase 3 NEXERA-303 topline readout, which is not expected until 2029, more than 12 months away. With no dated near-term binary catalyst, the impact score defaults low. Furthermore, INCA33890 is one of several pipeline assets at Incyte, a diversified biotech with approved revenue drivers (Jakafi, etc.), so this single drug does not comprise most of the company's value.
The next hard catalyst is the Phase 3 NEXERA-303 topline readout, but that is not expected until 2029, more than 12 months away. Investors should watch for interim Phase 1/2 combination updates (including the new muzastotug combo trial) and any biomarker data that could refine the Phase 3 probability of success. Incyte's Q3 2026 earnings were reported today (Oct 29, 2026); pipeline updates in the earnings call may provide additional color on NEXERA-303 enrollment.
Price Chart
Executive Summary
INCA33890 is Incyte's investigational PD-1/TGFβR2 bispecific antibody designed to overcome immunotherapy resistance in MSS colorectal cancer (a large market where checkpoint inhibitors generally fail). Phase 1 data at ESMO 2025 showed a 12% partial-response rate as monotherapy in MSS CRC. Updated ESMO 2026 data showed a 71.4% objective response rate when combined with FOLFOX/bevacizumab in first-line MSS CRC, supporting the ongoing Phase 3 NEXERA-303 trial. The Phase 3 study is enrolling at ~280 sites with topline data not expected until 2029, making this a mid-to-long-term pipeline story rather than a near-term binary catalyst for INCY shares.
How It Works
INCA33890 is a bispecific antibody, a single engineered protein that simultaneously blocks two targets: PD-1 (an immune checkpoint that tumors use to shut down T-cells) and TGFβ receptor 2 (a signaling pathway that suppresses immune responses in the tumor environment). By targeting both only on cells that co-express them, the drug aims to restore the immune system's ability to attack tumors, particularly in types of colorectal cancer that do not respond to standard PD-1/L1 inhibitors alone.
Trial Status
Phase 1 monotherapy and combination dose-escalation/expansion completed, presented at ESMO 2025 and ESMO 2026. The Phase 3 NEXERA-303 trial (NCT07284849) is actively recruiting at approximately 280 sites for first-line metastatic MSS colorectal cancer, with 700 patients targeted. A Phase 2 adjuvant trial (NEXERA-204, NCT07823322) is also underway for ctDNA-positive stage II/III MSS CRC after curative resection. A separate Phase 1 combination trial with Adagene's muzastotug (anti-CTLA-4) dosed its first patient on October 28, 2026.
The Two-Sided Case
Upcoming Catalysts
- Phase 1 combination data updates for INCA33890 + muzastotug (anti-CTLA-4) in MSS CRC (ongoing)
- Further biomarker and expansion cohort data from the Phase 1 program
- NEXERA-303 (Phase 3) enrollment updates
- NEXERA-204 (Phase 2 adjuvant) data in ctDNA-positive stage II/III MSS CRC
Source Filing
The SecBot filing or press-release report that triggered this drug report:
INCYTE CORP 8-K INCY ·Originating report